Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3017% below fair value
$1.98−0.18 (-8.33%)
Close on Nov 12, 2026Market cap $24.73MP/E –Yield –
Aligos Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Aligos Therapeutics's price to sales ratio was 3.6× on Nov 11, 2026, against 22.5× a year earlier. Over the last 4 years it ranged from 3.6× to 346.6×, with a median of 10.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.6× | −18.3 |
| 2025 | Dec 31, 2025 | 21.9× | −14.2 |
| 2024 | Dec 31, 2024 | 36.0× | +30.8 |
| 2023 | Dec 29, 2023 | 5.2× | – |
See a number that looks wrong?